WuXi PharmaTech’s analytical and stability testing facilities in Shanghai Waigaoqiao Free Trade Zone, have passed a GMP inspection by the FDA. The inspection also included clinical trial materials manufacturing for drug products (CTM), packaging and labeling facilities, which were deemed compliant.
"This favorable FDA inspection outcome, in addition to last year's MPA (EMA) approval, reflects the quality of our analytical and stability testing and CTM facilities, the robustness of our quality assurance system, and the high caliber of our employees," said Dr. Ge Li, Chairman and chief executive officer of WuXi PharmaTech. "We are committed to building operations with the highest standards of quality across our entire platform of R&D services."
WuXi PharmaTech’s Shanghai Facilities Pass FDA Audit
Published April 30, 2014
Related Breaking News
Related Online Exclusives